DNA topoisomerase I poisons.
Takimoto
C H
CH
NCI-Navy Medical Oncology Branch, Naval Hospital Bethesda, MD 20889-5105, USA.
Kieffer
L V
LV
Kieffer
M E
ME
Arbuck
S G
SG
Wright
J
J
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D000998:Antiviral Agents / Q000494:pharmacology; D002166:Camptothecin / Q000031:analogs & derivatives / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D004264:DNA Topoisomerases, Type I / Q000737:chemistry / Q000502:physiology; D019008:Drug Resistance, Neoplasm; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006801:Humans; D000077146:Irinotecan; D011838:Radiation-Sensitizing Agents / Q000494:pharmacology; D059004:Topoisomerase I Inhibitors; D019772:Topotecan / Q000494:pharmacology
D000970:Antineoplastic Agents; D000998:Antiviral Agents; D004791:Enzyme Inhibitors; D011838:Radiation-Sensitizing Agents; D059004:Topoisomerase I Inhibitors; C080125:9-aminocamptothecin; D000077146:Irinotecan; D019772:Topotecan; D004264:DNA Topoisomerases, Type I; D002166:Camptothecin